CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / March 28, 2022 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:

Medspresso and Liviana are delighted to announce that their Premium Coffee and Extra Virgin Olive Oil ranges are now listed in 100+ independent brick and mortar stores in the greater Cape Town, South Africa region.

Since the launch of Medspresso and Liviana late-2021, the brands have grown significantly in the Western Cape, with the number of stockists increasing weekly. There has also been momentous growth on social media as the stockists share and promote the products on their platforms and websites. Below are a few of the premium stockists carrying our products:

Terbodore Café | The Conscious Kitchen | Kleinsky’s Delicatessen | Grande Provence Deli | Sans Community Grocer

“We launched relatively recently, and there has been an astounding level of interest in both brands. Our partners love the packaging and most of all the actual product – coffees, teas, and olive oils. The sales and marketing team is doing an outstanding job on the road and on social media – we are getting our name out there in a big way and people are noticing us. We are particularly excited about our many new and returning customers.

There is a simple recipe to the brands’ success – quality products and exceptional service to our partners and consumers. We have very specific criteria to be met when selecting new stockists and we are very conscious about choosing partners that share our brands’ values, beliefs, and ethics. Looking forward, we currently have 14 SKUs, and expect to have 42 SKUs on the shelves by the end of 2022.” says Michael Sachar CEO M2Bio Sciences – Food and Beverage.

‘’It was never about getting the products in as many stores as possible. Rather, it was about educating stockists and consumers one by one about the benefits of CBD combined with premium food and beverages. We spent a lot of time refining our supply chain and fine-tuning our efficiencies, which resulted in extremely happy customers. We are poised for expansion across South Africa with Johannesburg being our next city. We have set a goal of 600 stores by year-end.” addedJeff Robinson CEO of M2Bio Sciences.

About Wuhan General Group, Inc./ M₂Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx, Medspresso, and Liviana brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Publicly traded company (OTC Pink: WUHN)
Visit Website
Contact via E-mail

Medspresso

Follow us on Twitter
Follow us on TikTok
Follow us on Facebook
Follow us on YouTube
Follow us on Instagram

Liviana

Follow us on Twitter
Follow us on LinkedIn
Follow us on Facebook
Follow us on Instagram

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./ M₂Bio Sciences, Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

CAPE TOWN, SA / ACCESSWIRE / January 19, 2022 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:

Wuhan General Group, Inc./M2Bio Sciences, Inc. is excited to announce the launch of Neurai Life Sciences.

Neurai Life Sciences is a pre- and clinical-stage biotechnology company focusing on the drug discovery and development of next generation therapies treating mental health disorders. The company will lead the industry in artificial intelligence-driven target discovery, innovative and sustainable small molecule chemistry, and inclusive clinical development in the pursuit of novel therapeutics for major depressive disorder, anxiety disorders, and addiction. Neurai Life Sciences is primed to realize the infinite potential of targeted therapeutics within the brain serotonin receptor-mediated signaling pathways.

With the goal of hiring the best international talent, Neurai Life Sciences has recruited Riyad Domingo Ph.D. as Chief Executive Officer. Dr. Domingo is the current Harvard South Africa Fellow for 2021-2022 and holds a doctorate in Medical Biochemistry with a focus on drug discovery and development from the Institute of Infectious Diseases and Molecular Medicine at the University of Cape Town.

“The consequences of the COVID-19 pandemic have underscored the need for the advancement of neuropsychiatric medicine. Mental illness affects everyone, so we at Neurai believe that our targeted drug development process should consider and include all individuals, independent of age, race, or gender. We leverage emerging technologies including machine learning and novel formulation methods, accompanied by well-established industry approaches, thereby driving the evolution of the mental health industry and how therapeutics are developed in the future. This is absolutely vital for the future of our mental health.” said Dr. Domingo.

Jeff Robinson, Wuhan General Inc, CEO added: “Neurai Life Sciences will pioneer a new field of neuropsychiatric medicine. The company will revolutionize and challenge conventional approaches to developing and treating mental health conditions with new medicines and therapies. With Dr. Domingo at the helm, we know that these new technologies will change the lives of millions globally. Neurai is recruiting the brightest minds in the fields of AI and pharma to further complement the ground-breaking technologies and portfolio of molecular assets that are currently in development under Neurai Life Sciences. Never has there been a greater need to combine technology and medicine to address the global mental illness pandemic.”

At this time, Neurai Life Sciences is a private company and 100% owned by Wuhan General Inc. Neurai Life Sciences will be conducting a capital raise to fund initial preclinical research, development, and validation of select drug candidates.

All Wuhan General Inc. shareholders interested in investing in the capital raise for Neurai Life Sciences or for further information, contact Jeff Robinson, Chief Executive Officer, at [email protected] or our web site found here. It is anticipated Neurai Life Sciences will seek a liquidity event for its shareholders at a later date. More details to follow.

About Wuhan General Group, Inc./ M₂Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx, Medspresso, and Liviana brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Publicly traded company (OTC Pink: WUHN)

Website: www.neurai.life
E-mail: [email protected]
Follow us on LinkedIn: Neurai Life Sciences
Website: www.m2bio.co
E-mail: [email protected]

Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio
Follow us on YouTube: https://www.youtube.com/channel/M2BioSciences
Follow us on Instagram: https://www.instagram.com/m2bio.sciences

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./ M₂Bio Sciences, Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

CAPE TOWN, SA / ACCESSWIRE / August 5, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research, is pleased to announce the following corporate update:

The research team funded by Wuhan General Group has successfully published a third paper on psychedelic science. The paper entitled “Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells“ has been released on the Dovepress platform (the first published paper can be found here and the second paper can be found here.)

The following is an excerpt from the newly published study:

“Psilocybin-containing mushrooms are mainly studied with reference to their anti-depressant effects and very little information is known towards their anti-inflammatory potential. We have previously reported in vitro antioxidant and anti-inflammatory effects of Psilocybe natalensis, one of the well-known magic mushrooms that grows in South Africa on the RAW 267.4 macrophage.²⁴ This study aimed at investigating further the anti-inflammatory effects of four psilocybin-containing mushrooms (Panaeolus cyanescens, Psilocybe natalensis, Psilocybe cubensis and Psilocybe cubensis leucistic A+ strain) from genus Panaeolus and Psilocybe for the first time in vitro on 15-lipoxygenase activity, and also on lipopolysaccharide (LPS)-induced inflammation in human U937 macrophage cells. The human U937 macrophage cell line has been widely used and categorized as a model of mammalian cellular response to various inflammatory stimuli.²⁵ We used hot-water extracts of the four mushrooms, which is one of the common methods of consumption used by magic mushroom users.”

“The extracts showed potential potent anti-inflammatory properties that could be beneficial in chronic inflammatory disease treatment.”

“This is another great milestone for the research team, the company and the psychedelic industry as the findings are very remarkable. The anti-inflammatory effects are groundbreaking and the potential treatments it may offer to medicine are extraordinary. The research team led by Sanah M. Nkadimeng is making monumental progress in bringing concrete psychedelics research to the forefront of medicine. Paper #4 is ready for submission and we are very excited to share the findings in the near future,” said Wuhan General Group CEO Jeff Robinson.

About Wuhan General Group, Inc./ M₂Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M₂Bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx, Medspresso and Liviana brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC Pink: WUHN)
Website: www.m2bio.co
E-mail:[email protected]

Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./M₂Bio Sciences, Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.